Sorrento therapeutics

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500


Beste broker van 2020 (volgens Beleggers Belangen)
Profiteer van voorbeurs en nabeurs handelen!
Aandelen kopen voor €3.000: €1,80 kosten (o.a. BE&NL)
Vraag het informatiepakket van MeXeM aan


MONEYCAT
Forum actieveling
Forum actieveling
Berichten: 295
Lid geworden op: 28 mar 2019 23:43
waarderingen: 149

Re: Sorrento therapeutics

Bericht door MONEYCAT »

Van Yahoo Finance

Het feit dat insiders al een jaar niet meer verkopen en uiteraard dat Dr. Ji z'n 4,9 miljoen aandelen niet verkocht toen Sorrento de $ 19 bereikte, doet mij er ten volle blijven in geloven ! :up:

CEO Dr Ji is holding more than 4.9 million shares, he hasn't sold any shares when the stock price was over $19 last year and no insiders has sold any shares last 12 month. This is one of the most important reason why I am holding 12k shares Sorrento long and strong since May.
Dr Ji thinks Sorrento will be worth more than 100 billion in 5 years, I have time and patience to wait because this is my long term investment.
maartenverhoeve liked last!





ancaoli
Forum elite
Forum elite
Berichten: 2132
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1173

Re: Sorrento therapeutics

Bericht door ancaoli »

Link is voor info over analist. Hierbij bevestiging koopadvies

B.Riley Financial Stick to Their Buy Rating for Sorrento Therapeutics
Investing.com | Apr 23, 2021 02:35AM ET

B.Riley Financial Stick to Their Buy Rating for Sorrento Therapeutics

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Sorrento Therapeutics (NASDAQ:SRNE) on Friday, setting a price target of $26, which is approximately 232.91% above the present share price of $7.81.
Mamtani expects Sorrento Therapeutics to post earnings per share (EPS) of -$0.25 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Sorrento Therapeutics, with an average price target of $25.
The analysts price targets range from a high of $30 to a low of $19.
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

sepan
Forum veteraan
Forum veteraan
Berichten: 1654
Lid geworden op: 08 aug 2012 08:08
waarderingen: 774

Re: Sorrento therapeutics

Bericht door sepan »

Dat we de goede kant op gaan....en gelijk ook weer wat meer volume :clap:

ancaoli
Forum elite
Forum elite
Berichten: 2132
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1173

Re: Sorrento therapeutics

Bericht door ancaoli »

sepan schreef:
26 apr 2021 18:06
Dat we de goede kant op gaan....en gelijk ook weer wat meer volume :clap:
T’werd tijd maar we staan nog nergens. Afin, mijn laatste traders staan 1$ positief, tweede en derde positie traders heb nog een lange weg te gaan. Ben echter niet van plan iets te verkopen onder de 12. En 75% van volledige positie niet onder de 20.
maartenverhoeve liked last!
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

MONEYCAT
Forum actieveling
Forum actieveling
Berichten: 295
Lid geworden op: 28 mar 2019 23:43
waarderingen: 149

Re: Sorrento therapeutics

Bericht door MONEYCAT »

ancaoli schreef:
26 apr 2021 18:18
sepan schreef:
26 apr 2021 18:06
Dat we de goede kant op gaan....en gelijk ook weer wat meer volume :clap:
T’werd tijd maar we staan nog nergens. Afin, mijn laatste traders staan 1$ positief, tweede en derde positie traders heb nog een lange weg te gaan. Ben echter niet van plan iets te verkopen onder de 12. En 75% van volledige positie niet onder de 20.
Mijn positie met 1/3 verhoogd vandaag: heb het gevoel dat we niet meer ver af zijn van de “take-off”🚀 :twisted:

ancaoli
Forum elite
Forum elite
Berichten: 2132
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1173

Re: Sorrento therapeutics

Bericht door ancaoli »

Voor zij die het nog niet gelezen zouden hebben

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sorrento Therapeutics (NASDAQ:SRNE) on Monday, setting a price target of $30, which is approximately 295.26% above the present share price of $7.59.
_Jack_ liked last!
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

ancaoli
Forum elite
Forum elite
Berichten: 2132
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1173

Re: Sorrento therapeutics

Bericht door ancaoli »

Vers van de pers


Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma

27 seconds ago, 5:39 pm CEST
Via GlobeNewswire
Stocks mentioned: SRNE
Listen
Share
Save
STI-3031 was discovered from Sorrento's fully human G-MAB™ library.
Currently, six G-MAB antibodies are in Phase 1b through Phase 3 clinical trials in immuno-oncology and COVID-19 indications.
These clinical and pre-clinical G-MAB antibodies are expected to be the foundation for developing potent antibody drug conjugates (ADCs) and antibody drug nanoparticle albumin-bound (ADNAB) product candidates.
G-MAB antibodies have also been used for the generation and production of both CAR-T and DAR-T™ cells for treating hematological cancer and solid tumors.
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Over the last several months, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))) and its development partners have advanced into clinical development (Phase 1b through Phase 3 clinical trials) a number of fully human monoclonal antibodies (mAbs) for the treatment of COVID-19 and various cancers. This demonstrates the potential of the deep pipeline generated from Sorrento's proprietary G-MAB™ library, invented by Dr. Henry Ji, the Chairman and CEO of Sorrento. This G-MAB library is based on the use of RNA transcription for amplification of the antibody variable domains from over 600 donors. These donors were from both sexes and of multiple ethnicities, leading to a broad diversity of antibodies. In-depth analysis of deep sequencing DNA data showed that the G-MAB library contains more than 20 quadrillion (1016) distinct antibody sequences. The G-MAB library has fostered the development of several early and late-stage oncology programs that are currently in Phase 2 and Phase 3 clinical trials and neutralizing mAbs currently in a Phase 2 clinical trial directed against the spike protein of COVID-19 viruses.

Two independent anti-PD-L1 mAbs are now in Phase 2 and Phase 3 clinical studies. A PD-L1 mAb (STI-3031, also known as IMC-001) was licensed to ImmuneOncia Therapeutics, Inc. ("ImmuneOncia"), a joint venture between Sorrento and Seoul-based Yuhan Corporation. IMC-001 has completed a Phase 1b study in patients with metastatic or locally-advanced solid tumors and is nearing completion of a Phase 2, open-label, "Neo-Chance" study in patients with resectable gastric cancer, esophageal cancer and liver cancer. ImmuneOncia has also started to enroll patients in a Phase 2 study in relapsed or refractory extranodal NK/T cell lymphoma, nasal type. Sorrento has filed an IND in the U.S. and received clearance from the FDA to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma.

A second antibody, Socazolimab, is licensed to Lee's Pharmaceutical Holdings Limited in the Greater China territory, and has been cleared to begin a multicenter Phase 3 trial as a potential first-line treatment for patients with extensive-stage small-cell lung cancer. Professor Shun Lu (Shanghai Chest Hospital) is the Principal Investigator. Additionally, Phase 1b studies in several other indications have been completed for this product candidate, including: recurrent metastatic cervical cancer, advanced urothelial carcinoma, and high-grade osteosarcoma after adjuvant chemotherapy for maintenance. In addition, a Phase 1b/2 study has been initiated as a potential neoadjuvant treatment option for esophageal carcinoma. For cervical cancer, a pivotal study has been completed with a breakthrough therapy designation granted by the National Medical Products Administration (NMPA) in China. Sorrento intends to open an IND in the U.S. with the intent to have an end-of-phase 3 meeting or pre-NDA discussion with the FDA for various cancer indications.

Sorrento previously announced FDA clearance to commence a Phase 1b study in various relapsed or refractory solid tumors with an anti-CD47 antibody (STI-6643) (a CD-47 checkpoint inhibitor interacting with SIRPα). In preclinical studies, STI-6643 appears to have a beneficial toxicity profile (e.g., reduced hemolysis) without a priming mechanism while maintaining potent anti-tumor activity. Additionally, Sorrento licensed a separate promising anti-CD47 antibody (IMC-002) to ImmuneOncia, which has initiated a Phase 1b study in patients with metastatic or locally-advanced solid tumors and relapsed or refractory lymphomas.

Sorrento previously announced the formation of its subsidiary company - Adnab, Inc.,– which is focused on developing and commercializing ADNAB™ platform products for hematological malignancies and solid tumors based on an exclusive license from the Mayo Clinic. Sorrento intends to combine a variety of its proprietary mAbs in conjunction with the ADNAB technology platform, which was developed by Dr. Svetomir Markovic, M.D., Ph.D., and his research team at Mayo Clinic. This effort will potentially result in multiple next-generation ADNAB products. Since ADNABs can be designed to have one or two mAbs on the external surface, in addition to a chemotherapeutic payload, the cytotoxic payload can potentially be delivered preferentially to targeted cancer cell types. Sorrento expects to develop a number of innovative ADNABs in anticipation of filing INDs for clinical trials later in 2021.

"These are very exciting times for Sorrento," said Dr. Ji. "These therapeutic antibody examples demonstrate that we are leveraging the G-MAB library to bring product candidates rapidly from preclinical development through the IND process and into clinic trials."
Brammeke liked last!
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

MONEYCAT
Forum actieveling
Forum actieveling
Berichten: 295
Lid geworden op: 28 mar 2019 23:43
waarderingen: 149

Re: Sorrento therapeutics

Bericht door MONEYCAT »

ancaoli schreef:
27 apr 2021 17:41
Vers van de pers


Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma

27 seconds ago, 5:39 pm CEST
Via GlobeNewswire
Stocks mentioned: SRNE
Listen
Share
Save
STI-3031 was discovered from Sorrento's fully human G-MAB™ library.
Currently, six G-MAB antibodies are in Phase 1b through Phase 3 clinical trials in immuno-oncology and COVID-19 indications.
These clinical and pre-clinical G-MAB antibodies are expected to be the foundation for developing potent antibody drug conjugates (ADCs) and antibody drug nanoparticle albumin-bound (ADNAB) product candidates.
G-MAB antibodies have also been used for the generation and production of both CAR-T and DAR-T™ cells for treating hematological cancer and solid tumors.
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Over the last several months, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))) and its development partners have advanced into clinical development (Phase 1b through Phase 3 clinical trials) a number of fully human monoclonal antibodies (mAbs) for the treatment of COVID-19 and various cancers. This demonstrates the potential of the deep pipeline generated from Sorrento's proprietary G-MAB™ library, invented by Dr. Henry Ji, the Chairman and CEO of Sorrento. This G-MAB library is based on the use of RNA transcription for amplification of the antibody variable domains from over 600 donors. These donors were from both sexes and of multiple ethnicities, leading to a broad diversity of antibodies. In-depth analysis of deep sequencing DNA data showed that the G-MAB library contains more than 20 quadrillion (1016) distinct antibody sequences. The G-MAB library has fostered the development of several early and late-stage oncology programs that are currently in Phase 2 and Phase 3 clinical trials and neutralizing mAbs currently in a Phase 2 clinical trial directed against the spike protein of COVID-19 viruses.

Two independent anti-PD-L1 mAbs are now in Phase 2 and Phase 3 clinical studies. A PD-L1 mAb (STI-3031, also known as IMC-001) was licensed to ImmuneOncia Therapeutics, Inc. ("ImmuneOncia"), a joint venture between Sorrento and Seoul-based Yuhan Corporation. IMC-001 has completed a Phase 1b study in patients with metastatic or locally-advanced solid tumors and is nearing completion of a Phase 2, open-label, "Neo-Chance" study in patients with resectable gastric cancer, esophageal cancer and liver cancer. ImmuneOncia has also started to enroll patients in a Phase 2 study in relapsed or refractory extranodal NK/T cell lymphoma, nasal type. Sorrento has filed an IND in the U.S. and received clearance from the FDA to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma.

A second antibody, Socazolimab, is licensed to Lee's Pharmaceutical Holdings Limited in the Greater China territory, and has been cleared to begin a multicenter Phase 3 trial as a potential first-line treatment for patients with extensive-stage small-cell lung cancer. Professor Shun Lu (Shanghai Chest Hospital) is the Principal Investigator. Additionally, Phase 1b studies in several other indications have been completed for this product candidate, including: recurrent metastatic cervical cancer, advanced urothelial carcinoma, and high-grade osteosarcoma after adjuvant chemotherapy for maintenance. In addition, a Phase 1b/2 study has been initiated as a potential neoadjuvant treatment option for esophageal carcinoma. For cervical cancer, a pivotal study has been completed with a breakthrough therapy designation granted by the National Medical Products Administration (NMPA) in China. Sorrento intends to open an IND in the U.S. with the intent to have an end-of-phase 3 meeting or pre-NDA discussion with the FDA for various cancer indications.

Sorrento previously announced FDA clearance to commence a Phase 1b study in various relapsed or refractory solid tumors with an anti-CD47 antibody (STI-6643) (a CD-47 checkpoint inhibitor interacting with SIRPα). In preclinical studies, STI-6643 appears to have a beneficial toxicity profile (e.g., reduced hemolysis) without a priming mechanism while maintaining potent anti-tumor activity. Additionally, Sorrento licensed a separate promising anti-CD47 antibody (IMC-002) to ImmuneOncia, which has initiated a Phase 1b study in patients with metastatic or locally-advanced solid tumors and relapsed or refractory lymphomas.

Sorrento previously announced the formation of its subsidiary company - Adnab, Inc.,– which is focused on developing and commercializing ADNAB™ platform products for hematological malignancies and solid tumors based on an exclusive license from the Mayo Clinic. Sorrento intends to combine a variety of its proprietary mAbs in conjunction with the ADNAB technology platform, which was developed by Dr. Svetomir Markovic, M.D., Ph.D., and his research team at Mayo Clinic. This effort will potentially result in multiple next-generation ADNAB products. Since ADNABs can be designed to have one or two mAbs on the external surface, in addition to a chemotherapeutic payload, the cytotoxic payload can potentially be delivered preferentially to targeted cancer cell types. Sorrento expects to develop a number of innovative ADNABs in anticipation of filing INDs for clinical trials later in 2021.

"These are very exciting times for Sorrento," said Dr. Ji. "These therapeutic antibody examples demonstrate that we are leveraging the G-MAB library to bring product candidates rapidly from preclinical development through the IND process and into clinic trials."
M’n voorgevoel van gisteren was juist...geluk is af en toe eens welkom let’s go 🚀

MONEYCAT
Forum actieveling
Forum actieveling
Berichten: 295
Lid geworden op: 28 mar 2019 23:43
waarderingen: 149

Re: Sorrento therapeutics

Bericht door MONEYCAT »

We zijn terug door de 9 : ziet er goed uit !✈️
_Jack_ liked last!

ancaoli
Forum elite
Forum elite
Berichten: 2132
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1173

Re: Sorrento therapeutics

Bericht door ancaoli »

Alé, nog 10$ erbij en we mogen terug tussen de mensen ;). Als je Vaxart vandaag ziet, + 50% zonder echt nieuws dan kan dit ook bij SRNE op een wip gebeuren. En dan nog een shortsqeeze en t'is echt feest. Dromen mag...
MONEYCAT liked last!
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva







Plaats reactie